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Introduction
Cystic fibrosis (CF) is the most common inherited lethal disease 
in Caucasians. It is caused by mutations in the cystic fibrosis 
transmembrane conductance regulator encoded by the CFTR 
gene encoding a membrane chloride transporter.1-3 The patho-
genic factors in CF airway disease include defective innate 
antimicrobial activity, altered mucociliary clearance, abnormal 
submucosal gland function and overproduction of reactive oxy-
gen species (ROS).4-6 Chronic inflammation is most central to 
CF pathogenesis as a consequence to pulmonary infections and 
leads to lung damage resulting in 85% of the deaths.7-10 Human 
and mouse CF airway epithelia are autophagy deficient and 
exhibit highly reduced autophagosome formation.11,12 Autophagy 
is a conserved physiological process that eliminates nonfunc-
tional organelles and recycles cytosolic components for the gen-
eration of nutrients during periods of stress or starvation.13,14 
cystic fibrosis (cF) is the most common inherited lethal disease in caucasians which results in multiorgan dysfunction. 
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Autophagy targets cytosolic long-lived proteins and organelles 
for lysosomal degradation in eukaryotic cells and plays a role in 
innate immunity.15 Autophagy has been linked to a variety of 
disease states, including cancer, myopathies, neurodegeneration, 
Crohn disease, infection and inflammation.13,16-18 Formation of 
autophagosomes depends on a lipid kinase signaling complex 
containing class III PI3K and two ubiquitin-like conjugation 
pathways that activates expansion of the pre-autophagosomal 
membrane.19,20 The Atg12-Atg5-Atg16L complex is attached to 
the nascent autophagosome and recruits Atg8—microtubule-
associated protein 1 light chain 3 (LC3)—which is expressed ini-
tially as an unprocessed form. Then, pro-LC3 is cleaved by Atg4 
to generate an active form, LC3-I.21 LC3-I interacts with phos-
phatidylethanolamine (PE), yielding LC3-II.15,22,23 Therefore the 
transformation of LC3I to LC3II denotes autophagy stimulation 
and autophagosome formation. Subsequently, the Atg12-Atg5-
Atg16L complex detaches from the formed autophagosome.23,24 
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B. cepacia to the lysosome for degradation. Rapamycin treatment 
also dramatically decreases the recruitment of inflammatory 
cells to the lungs of infected CF mice. Taken together, our data 
provide a preponderance of evidence that B. cepacia exploits the 
already defective autophagy pathway in ΔF508 macrophages to 
establish infection. Stimulating autophagy activity with rapamy-
cin restores the ability of ΔF508 macrophages to control B. cepa-
cia infection and the associated inflammation. Therefore, our 
studies support the notion that pharmacological stimulation of 
autophagy will be beneficial for CF patients to prevent B. cepa-
cia infection and thwart the detrimental inflammatory response 
within the lungs of CF patients.
Results
Macrophages harboring the CFTR ΔF508 mutation support 
increased B. cepacia survival and produce more IL-1β than 
WT macrophages. We examined whether B. cepacia had a sur-
vival advantage in primary murine macrophages expressing the 
CFTR protein harboring the ΔF508 mutation, which is the most 
common mutation in CF patients.60-62 WT and CFTR ΔF508 
(ΔF508) macrophages were infected with the B. cepacia clinical 
isolate K56-2 and colony-forming units (CFU) were determined 
from lysed infected macrophages at 30 min (Fig. S1) and at 24 
h post-infection (Fig. 1A). We found that more B. cepacia was 
recovered from ΔF508 macrophages than WT cells after 24 h 
of infection (Fig. 1A), whereas, the initial uptake was similar in 
both cells (Fig. S1). We next examined the number of B. cepa-
cia associated with WT and ΔF508 macrophages by confocal 
microscopy. WT and ΔF508 macrophages were infected with 
red fluorescent protein (mRFP)-expressing B. cepacia for 30 min 
and 2 h and the number of B. cepacia associated with 100 mac-
rophages was evaluated. At an early time point (30 min post-
infection) similar numbers of B. cepacia were associated with WT 
and ΔF508 macrophages (Fig. S2). In contrast, at 2 h there were 
<200 B. cepacia associated with 100 WT macrophages (Fig. 1B 
and C), whereas there were >300 B. cepacia associated with 100 
ΔF508 macrophages (Fig. 1B and C). Thus, these data are con-
sistent with the CFU data suggesting more growth of B. cepacia 
in ΔF508 macrophages than in WT macrophages.
Since IL-1β is an essential pro-inflammatory cytokine that 
affects CF patients,50-58 we next determined the levels of active 
IL-1β in culture supernatants and found that ΔF508 macro-
phages produced significantly more IL-1β when infected with B. 
cepacia compared with WT cells (Fig. 1D). Yet, the mechanism is 
unclear. To rule out the role of macrophage survival in IL-1β pro-
duction differences, the release of lactate dehydrogenase (LDH) 
was evaluated in WT and ΔF508 macrophages infected with B. 
cepacia. The ΔF508 mutation did not alter macrophage survival 
in response to B. cepacia (Fig. S3). Therefore, primary macro-
phages expressing the ΔF508 mutation support increased B. cepa-
cia intracellular survival and bacterial replication and produce 
more IL-1β during B. cepacia infection.
The B. cepacia-containing intracellular vacuole acquires 
autophagy characteristics in WT macrophages but not in 
ΔF508 macrophages. Since autophagy activity is compromised 
This uncoating event enables the autophagosome to fuse with the 
lysosome. A small GTP binding protein Rab7 and the lysosomal 
associated membrane proteins 1 and 2 (LAMP1, LAMP2) are 
needed for this process.20,25-27 Many pharmacological agents have 
been reported to induce autophagy, such as rapamycin, an inhibi-
tor of the mTOR pathway (mammalian target of rapamycin). 
The mTOR pathway is active in the presence of nutrients and 
negatively regulated by starvation or rapamycin and, under these 
conditions, autophagy is activated.28
Autophagy contributes to the control of a variety of bacterial 
and viral infections. For example, Group A Streptococcus that 
escapes from the endosome is targeted to the autophagosome, 
and Atg5 deletion delays its clearance.29,30
Similarly, during Listeria monocytogenes infection, bacterial 
listeriolysin-O toxin-mediated escape from phagosomes induces 
autophagy.30-32 Furthermore, a subset of Salmonella enterica-
containing vacuoles is targeted to autophagosomes, and Atg5 
deletion also allows for more bacterial survival.33 Interestingly, 
Mycobacteria-containing vesicles are targeted to autophago-
somes, which decreases mycobacterial survival.34 The antimicro-
bial role of autophagy has been extended to viral infections such 
as human immunodeficiency virus (HIV).35,36
Burkholderia cenocepacia (B. cepacia) is an opportunistic, 
multidrug-resistant bacterium that infects CF patients leading 
to severe inflammation followed by destruction of the lung tis-
sue, sometimes resulting in necrotizing pneumonia leading to 
patient death.37,38 Unfortunately, B. cepacia is resistant to essen-
tially all antibiotics and thus impossible to treat. B. cepacia adopts 
an extracellular or intracellular lifestyle.39,40 The bacterium can 
survive within a variety of eukaryotic cells such as amoebae, epi-
thelial cells and human macrophages.41-46
The B. cepacia-containing vacuole within macrophages delays 
acidification, does not assemble the NADPH-oxidase complex 
and fails to activate Rab7.43,47-49 These phenotypes are further 
exaggerated in CFTR-defective macrophages. However, little is 
known regarding the nature of the compartment harboring B. 
cepacia and the mechanism by which the bacteria delay its deliv-
ery to the lysosome for degradation.
During B. cepacia infection, abundant inflammatory cyto-
kines such as IL-1β are detected in the bronchoalveolar lavage 
(BAL) of CF patients.50-58 IL-1β is primarily expressed as a precur-
sor inactive molecule, which is later cleaved by caspase-1 to yield 
active 17-kDa IL-1β.59 The biological activities of IL-1β include 
promoting inflammatory responses and leukocyte infiltration.
Here we show that in WT macrophages a moderate number of 
B. cepacia-containing vacuoles are labeled with the specific auto-
phagy marker LC3 within 2 h post-infection. B. cepacia contain-
ing vacuoles delay the fusion with the lysosome for several hours. 
Notably, B. cepacia decreases the expression of essential autophagy 
molecules. This B. cepacia-mediated effect is exacerbated in 
ΔF508 cells which are intrinsically defective in autophagy activ-
ity.11,12 In ΔF508 macrophages, B. cepacia-containing vacuoles 
do not fuse with the lysosomes and do not have autophagosome 
characteristics. We demonstrate that this defect is reversible since 
stimulation of autophagy with rapamycin decreases the bacte-
rial burden in vitro and in vivo by accelerating the delivery of 
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WT macrophages further confirmed that B. cepacia downregu-
lates autophagy and that this effect is more profound in ΔF508 
macrophages (Fig. 2E). On the other hand, other autophagy-
interacting bacteria such as Salmonella induce the expression of 
several autophagy molecules during infection (data not shown). 
Therefore, it appears that the downregulation of essential auto-
phagy molecules is a strategy employed by B. cepacia to delay the 
maturation of autophagosomes and hence avoid clearance by the 
host cell. The B. cepacia-mediated downregulation of autophagy 
genes is similar in WT and ΔF508 macrophages but the effect is 
more pronounced in the latter cells suggesting that they harbor 
an inefficient autophagy system as described in ΔF508 epithelial 
cells.11,12
Depletion of LC3 from WT macrophages allows for more 
B. cepacia recovery and increased IL-1β production. B. cepa-
cia infection downregulates autophagy genes in both WT and 
ΔF508 macrophages, but the effect on autophagy activity is 
more pronounced in ΔF508 macrophages, suggesting a possible 
in CF epithelial cells we examined whether macrophages have 
the same defect by observing their autophagy response dur-
ing the B. cepacia infection.11,12 WT and ΔF508 macrophages 
were infected with mRFP-expressing B. cepacia for 2 h. The 
acquisition of endogenous LC3 by the B. cepacia-containing 
vacuole was assessed with specific antibodies by confocal 
microscopy. In WT macrophages, 20% B. cepacia-containing 
vacuoles were labeled with the specific autophagy marker LC3 
within 2 h infection (Fig. 2A and C). Several LC3-labeled 
vacuoles (puncta) were identified in WT macrophages (Fig. 
2A; white arrows). In contrast, B. cepacia-containing vacu-
oles in ΔF508 macrophages had rare LC3-labeled structures 
(puncta) in response to B. cepacia compared with WT macro-
phages and only 10% of mRFP-expressing B. cepacia-contain-
ing vacuoles showed co-localization with LC3 (Fig. 2B and 
C). Notably, as shown earlier, greater numbers of B. cepacia 
were visualized in ΔF508 macrophages than in WT cells at 
2 h post-infection (Fig. 2A and B). To further confirm the 
identity of the B. cepacia-containing compartment, B. cepa-
cia-infected WT and ΔF508 macrophages were examined by 
transmission electron microscopy. Infected WT macrophages 
contained few B. cepacia and they were surrounded by several 
multilamellar membranes (Fig. 2D; black arrows) similar to 
autophagosomes and showed signs of bacterial degradation. 
In contrast, in ΔF508 macrophages, several intact B. cepacia 
were associated with the macrophage (Fig. 2D; white arrow 
heads), and they lacked the autophagosome-like structure. 
Immunofluorescence quantification of puncta within infected 
macrophages also confirmed that the autophagy response 
is compromised in ΔF508 macrophages during B. cepacia 
infection (Fig. 2E). Together, these data indicate that the 
autophagy response of ΔF508 macrophages to B. cepacia is 
significantly less than that of WT macrophages and hence 
more B. cepacia are enclosed in autophagosome-like vacuoles 
within WT macrophages.
B. cepacia downregulates autophagy genes during infec-
tion of WT and ΔF508 macrophages. B. cepacia resides 
within LC3 labeled compartments reminiscent of auto-
phagosomes in WT macrophages with the presence of puncta 
in several macrophages (Fig. 2). However, compared with WT 
macrophages infected with other organisms such as Salmonella, 
there were many fewer puncta in WT macrophages infected with 
B. cepacia (Fig. 2E and data not shown).13,14,63 Nevertheless, sig-
nificantly fewer puncta were detected in ΔF508 macrophages 
when compared with WT macrophages infected with B. cepacia 
(Fig. 2E). The cause of this observation is unknown. To examine 
the effect of B. cepacia on the autophagy pathway, we performed 
an array analysis for a part of autophagy genes in B. cepacia-
infected WT and ΔF508 macrophages. B. cepacia infection led 
to a significant downregulation of several autophagy genes such 
as Atg9b, Atg5, Atg12 (Fig. 3A) and Atg8 (Fig. 3B) in ΔF508 
and in WT macrophages (Fig. S4A and B). Quantitative PCR 
(qPCR) and protein gel blot analysis confirmed the downregu-
lation of autophagy genes and their corresponding protein in 
both cell types (Figs. 3A, C–E and 2E and data not shown). The 
low number of puncta in ΔF508 macrophages compared with 
Figure 1. Macrophages harboring ΔF508 mutation show more B. cepacia 
recovery and enhanced cytokine production from macrophages. (A) Wild-
type (Wt) or CFTRΔF508 (ΔF508) murine bone marrow-derived macro-
phages (BMDM) were infected with B. cepacia and colony-forming units 
(cFUs) were enumerated at 24 h post-infection. (B) confocal microscopy of 
Wt or ΔF508 BMDM after 2 h of infection with B. cepacia. Nuclei are stained 
blue with DAPi and B. cepacia expresses red florescent protein. White ar-
rows indicate the sites of B. cepacia. (c) scoring of the number of B. cepacia 
associated with 100 BMDMs in confocal images. (D) 24 h post-infection, 
supernatants from BMDM from Wt or ΔF508 mice were analyzed for iL-1β. 
Data are representative of 3 independent experiments and presented as 
the means ± sD. Asterisks in (c and e) indicate significant differences (*p < 
0.05 and ***p < 0.0001).
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(Fig. 4C and D). Therefore, compromising autophagy in WT 
macrophages with specific siRNA produced a ΔF508-like pheno-
type, such as increased B. cepacia recovery and enhanced IL-1β 
release.
Once activated, caspase-1 cleaves pro-IL-1β to its active form, 
which is then released into culture supernatants. Therefore, to 
understand why IL-1β release is increased in ΔF508 macrophages 
during B. cepacia infection, we compared the levels of IL-1β pro-
form in ΔF508 and WT macrophages upon B. cepacia infection. 
The depletion of LC3 with specific siRNA in WT and ΔF508 
macrophages increased the levels of pro-IL-1β in macrophages 
in response to B. cepacia infection (Fig. S5B) and led to more 
active IL-1β released into culture supernatants (Fig. 4C and D). 
Therefore, decreasing autophagy activity resulted in increased 
pro-IL-1β accumulation, activation and release of active IL-1β in 
response to B. cepacia infection.
Stimulation of autophagy by rapamycin decreases B. cepa-
cia recovery and IL-1β production in vitro. Macrophages har-
boring ΔF508 mutation show increased intracellular survival 
mechanism allowing for increased B. cepacia survival. This could 
be due to defective autophagy activity in macrophages harbor-
ing mutant CFTR protein similar to epithelial cells expressing 
the same mutation.11,12 Therefore, we examined if compromising 
autophagy in WT macrophages would result in a similar phe-
notype to ΔF508 macrophages. We reduced autophagy activity 
in WT macrophages by depleting LC3, an essential autophagy 
molecule. The depletion of LC3 was achieved with specific small 
interfering RNA (siRNA) to LC3 and confirmed by protein gel 
blots using specific antibody that recognizes LC3I and LC3II 
forms (Fig. S5A). Initial uptake of B. cepacia was similar in WT 
and ΔF508 macrophages pretreated with siRNA-LC3 or siRNA-
control (CT) (data not shown). Depletion of LC3 in WT mac-
rophages by specific siRNA was accompanied by an increased 
recovery of B. cepacia (Fig. 4A). Depletion of LC3 in ΔF508 mac-
rophages was accompanied by an increase in B. cepacia recovery 
although less significant (Fig. 4B). The decrease in LC3 expres-
sion was associated with increased secretion of the active form 
of IL-1β from B. cepacia-infected WT and ΔF508 macrophages 
Figure 2. B. cepacia resides in an autophagosome-like compartment in macrophages. (A and B) confocal microscopy for wild-type (Wt) murine BMDM 
(A) and BMDM harboring ΔF508 mutation (ΔF508) (B) representing the colocalization of B. cepacia with Lc3/Atg8i after 2 h infection. Nuclei are stained 
with DAPi, B. cepacia expresses red florescent protein and Lc3/Atg8 is stained green with specific antibodies. White arrows indicate the presence of 
Lc3/Atg8. (c) the percentage of colocalization of B. cepacia with Lc3/Atg8 was scored. (D) transmission electron microscopy of murine BMDM express-
ing Wt or mutated ΔF508 cFtr protein after 2 h infection with B. cepacia. Black arrow indicates a mutilamellar autophagosome-like vacuole. White 
arrow heads indicate vacuoles containing intact bacteria within single-membrane vacuoles. (e) the scores for the percentage of puncta in 100 Wt 
and ΔF508 macrophages after 4 h infection with B. cepacia. Data are representative of 3 independent experiments and presented as the means ± sD. 
Asterisks in (c and e) indicate significant differences (*p < 0.05; **p < 0.01).
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6A and B). Therefore, rapamycin treatment stimulates autophagy 
and decreases the B. cepacia burden in vivo in ΔF508 mice.
Next, we determined the effect of rapamycin treatment on the 
inflammatory response of lung tissue of B. cepacia-infected mice. 
Histological examination of H&E stained lung sections of WT 
mice infected with B. cepacia revealed the preservation of most of 
the lung tissue with patchy areas of accumulation of inflammatory 
cells (Fig. 6C and left upper part). Lung sections of ΔF508 mice 
demonstrated significantly more pronounced and generalized 
recruitment of inflammatory cells (arrow head) throughout the 
lung tissue with peribronchiolar and perivascular infiltrates and 
hemorrhage (arrow) (Fig. 6C and left middle part). Higher mag-
nification of ΔF508 lung sections closely showed that B. cepacia 
and growth of B. cepacia (Fig. 1A and B). To 
investigate whether this phenotype is due to 
reduced autophagy activity in ΔF508 macro-
phages, we examined the effect of autophagy 
stimulation by rapamycin on B. cepacia-infected 
ΔF508 macrophages. Rapamycin is an inhibitor 
of the mammalian target of rapamycin (mTor) 
that induces autophagy.64,65 Macrophages were 
treated with rapamycin or with the drug vehicle 
DMSO before and after B. cepacia infection. 
The number of B. cepacia recovered was evalu-
ated at 2, 4 and 6 h post infection and expressed 
as CFUs/ml. Rapamycin significantly decreased 
the number B. cepacia recovered from WT and 
ΔF508 macrophages (Fig. 5A and B). However, 
the effect was observed in ΔF508 macrophages 
as early as 2 h post-infection despite equal initial 
uptake (Fig. 5B and data not shown). Adding 
rapamycin directly to bacterial cultures in the 
absence of macrophages did not alter B. cepacia 
survival (data not shown). By confocal micros-
copy, the number of B. cepacia associated with 
100 macrophages at 2 h post infection was sig-
nificantly lower in ΔF508 macrophages in the 
presence of rapamycin, thus confirming the CFU 
data (Fig. 5C). In contrast, the reduction in 
B. cepacia numbers recovered from infected WT 
macrophages was evident at later stages of infec-
tion (Fig. 5A).
We next investigated if rapamycin affects the 
levels of active IL-1β released in culture superna-
tants.66 In contrast to DMSO, rapamycin treat-
ment of ΔF508 macrophages markedly decreased 
IL-1β production in response to B. cepacia 
infection (Figs. 5D and S6A). Rapamycin also 
decreased IL-6 production (Fig. S6B and C). 
The levels of other cytokines such as TNFα were 
comparable in the presence or absence of rapamy-
cin at 24 h post-infection (Fig. S6D and E). 
Therefore, stimulation of autophagy by rapamy-
cin decreases the production of IL-1β and not all 
pro-inflammatory cytokines in response to B. 
cepacia infection in vitro.
Rapamycin treatment decreases the bacterial burden and 
reduces the signs of inflammation in the lungs of ΔF508 mice. 
Since B. cepacia infects the lungs of CF patients we used the 
ΔF508 mouse model for CF to examine if rapamycin treatment 
decreases the bacterial burden in vivo and if it alleviates inflam-
matory findings in the lungs of infected mice. WT and ΔF508 
mice were pretreated with two doses of rapamycin or DMSO by 
intra-peritoneal injections. Mice were then infected intra-trache-
ally with B. cepacia followed by an additional dose of rapamycin 
or DMSO. On the second day post-infection, mice were sacri-
ficed, lungs were collected and the bacterial burden was deter-
mined. Rapamycin treatment did not affect B. cepacia recovery 
from WT lungs but reduced it drastically from ΔF508 lungs (Fig. 
Figure 3. B. cepacia downregulates the expression of autophagy genes in murine mac-
rophages. (A and B) Bone marrow-derived macrophages (BMDMs) harboring the ΔF508 
mutation were either uninfected (No treatment) or infected with B. cepacia for 4 h and 
then the cells were lysed in trizol. rNA was extracted and sA Biosciences autophagy 
array analysis was performed for several autophagy genes (A) and for Lc3/Atg8 (B). (c) 
immunoblotting for Wt and ΔF508 murine macrophages showing the expression level 
of Lc3/Atg8 before and after 4 h infection with B. cepacia in the presence of rapamycin or 
DMso. (D and e) q-Pcr results for autophagy regulating genes 5 and 12 (Atg5, Atg12) in 
Wt and ΔF508 BMDMs non infected (white bars) or infected (gray bars) with B. cepacia for 
4 h. Data in (A, D and e) are expressed as relative copy numbers (rcN) and presented as 
means of 3 independent experiments ± sD. Asterisks indicate significant differences from 
the uninfected cells at the indicated time point (*p < 0.05).
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vacuole that acquired LC3 in both WT and ΔF508 macrophages 
(Fig. 7A; white arrows and B). Since rapamycin promoted the 
acquisition of LC3, we examined if it enables the delivery of B. 
cepacia to the lysosome. Green lysotracker, which accumulates 
in lysosomes, was added to rapamycin or DMSO-treated WT 
and ΔF508 macrophages prior to infection with mRFP-express-
ing B. cepacia. Almost 40% and 20% of B. cepacia localized 
with the lysotracker in DMSO-treated WT and ΔF508 mac-
rophages respectively within 2 h infection indicating that WT 
macrophages are more efficient in delivering B. cepacia to the 
lysosomes (Figs. 7A, B and S7). Rapamycin treatment slightly 
increased the number of B. cepacia that trafficked to the lyso-
some in WT macrophages. Nevertheless, rapamycin treatment 
significantly increased the delivery of B. cepacia to the lysosomes 
in ΔF508 macrophages up to 50% within 2 h (Figs. 7C, D and 
S7). Therefore, stimulation of autophagy by rapamycin drives the 
maturation of the B. cepacia-containing vacuole enabling it to 
fuse with the lysosome and thereby improving the clearance of 
the bacterium from ΔF508 macrophages.
Discussion
CF is the most common life-shortening inherited disease among 
the Caucasian population owing in part to the exaggerated 
infection also led to the accumulation of inflammatory cells and 
exudates in the alveolar spaces of ΔF508 lungs (Fig. 6C and left 
lower part). To determine whether rapamycin treatment rescues 
the appearance of the ΔF508 lung tissue during B. cepacia infec-
tion, mice were treated with rapamycin and infected intra-trache-
ally with B. cepacia as described above. H&E stained lung sections 
of rapamycin-treated mice showed that rapamycin treatment dras-
tically reduced the recruitment of inflammatory cells throughout 
the CF lung, prevented peribronchiolar and perivascular hemor-
rhage and preserved the alveolar space of infected ΔF508 mice 
(Fig. 6C and right middle and lower parts). Therefore, rapamycin 
treatment decreases inflammation and thus rescues the lung tissue 
in a mouse model of CF following B. cepacia infection.
Rapamycin treatment decreases B. cepacia recovery from 
ΔF508 macrophages by enhancing their delivery to lysosomes. 
Rapamycin treatment significantly decreased the recovery of B. 
cepacia from ΔF508 mice and their derived macrophages, yet the 
mechanism is unclear. It is possible that rapamycin-mediated 
induction of autophagy enhanced the maturation and the fusion 
of the B. cepacia-enclosing vacuole with the lysosomal compart-
ment. To explore the trafficking of B. cepacia within macrophages, 
the colocalization of mRFP-expressing B. cepacia with the auto-
phagy marker LC3 was determined in the presence of rapamy-
cin. Rapamycin increased the number of B. cepacia-containing 
Figure 4. Depletion of Lc3 with specific sirNA increases B. cepacia multiplication and interleukin-1β (iL-1β) secretion in macrophages. (A and B) Bone-
marrow derived macrophages (BMDMs) from Wt and ΔF508 mutant mice were nucleofected with sirNA against Lc3/Atg8 (sirNA-Lc3) or control sirNA 
(sirNA-ct) for 48 h and then infected with B. cepacia for 2, 4 and 6 h. colony forming units (cFUs) were enumerated. (c and D) Both types of macro-
phages were then infected for 6 and 8 h and supernatants were analyzed for iL-1β production. Data are representative of three different experiments 
and presented as the means ± sD. Asterisks indicate significant differences from the (sirNA-ct) at the respective time points (*p < 0.05; **p < 0.01; 
***p< 0.001).
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Interestingly, the small GTP-binding protein Rab7 is inactivated 
by B. cepacia.49 Rab7 is required for the final maturation of the 
late autophagic vacuole.70 Thus, this observation is consistent 
with the lack of autophagy markers on the B. cepacia vacuole in 
ΔF508 macrophages.
Our data suggest that the inherently defective autophagy 
activity in ΔF508 cells11,12 in concert with the downregulation 
of major autophagy genes and inactivation of Rab7 by B. cepacia 
contribute to the persistence of B. cepacia in ΔF508 macrophages.
Why CF patients are more prone to B. cepacia infection and 
not to other autophagy-interacting pathogenic bacteria such as 
Salmonella is unknown. It seems that despite its compromised 
activity in ΔF508 macrophages, autophagy is still effective in 
clearing other autophagy-interacting bacteria. One possibility is 
that other intracellular bacteria like Salmonella do not decrease 
the expression levels of autophagy molecules. Thus, the down-
regulation of autophagy gene expression appears to give B. cepa-
cia a survival advantage in ΔF508 macrophages. Suppression 
of autophagy has been employed by other pathogens such as 
Francisella or Listeria.71-73 Yet, it seems that their strong autoph-
agy-suppression capacity gives these pathogens a survival advan-
tage even in WT cells, unlike B. cepacia.
During B. cepacia infection, caspase-1 is activated and pro-
IL-1β is cleaved and released from infected macrophages.74 
pulmonary inflammatory response in the lungs of CF patients 
upon infection especially with B. cepacia.59,67,68 B. cepacia is trans-
missible among CF patients and impossible to eradicate due to 
its inherent antibiotic resistance. Why CF patients are specifi-
cally susceptible to B. cepacia is unknown. Here we demonstrate 
that B. cepacia has a survival advantage in ΔF508 macrophages 
as the number of B. cepacia associated with ΔF508 macrophages 
is strikingly higher than those associated with WT macrophages. 
The results raise the possibility that B. cepacia uses the macro-
phages as a sanctuary to evade host defense.
The nature of the B. cepacia-containing vacuole and the 
mechanism halting its fusion with the lysosome were unclear. 
Here we show that in WT macrophages, a fraction of intracellu-
lar B. cepacia resides in multilayered LC3-labeled compartments 
consistent with autophagosomes.69 A percentage of the B. cepacia-
containing autophagosomes fuses with the lysosome. In contrast, 
in ΔF508 macrophages, LC3 is not detected around the B. cepacia 
vacuole, which rarely fuses with the lysosome (Fig. 7C). Electron 
microscopy data (Fig. 2D) showed that in WT macrophages, a 
fraction of intracellular B. cepacia resides in multilayered vacuoles 
that resemble the autophagosomes while in ΔF508 macrophages, 
most bacteria remained inside single-membrane vacuoles.
Autophagy stimulation with rapamycin in ΔF508 mac-
rophages enhances the delivery of B. cepacia to the lysosomes. 
Figure 5. rapamycin treatment decreases the recovery of B. cepacia and interleukin-1β (iL-1β) production from infected macrophages. (A and B) Bone-
marrow derived macrophages (BMDMs) from Wt mice (A) and those harboring the ΔF508 mutation (B) were infected with B. cepacia for 2, 4 and 6 h 
in the presence of rapamycin or DMso. colony-forming units (cFUs) were enumerated. (c) Wt and ΔF508 were infected with B. cepacia for 2 h in the 
presence of rapamycin or DMso and then the number of bacteria per 100 macrophages was scored. (D) Wt and ΔF508 were infected with B. cepacia 
for 24 h in the presence of rapamycin or DMso and the supernatants were analyzed for iL-1β. Data are representative of 3 independent experiments 
and presented as means ± sD. Asterisks indicate significant differences from the DMso-treated cells (*p < 0.05; **p < 0.01).
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are autophagy deficient and rescued by cystamine, an autophagy-
inducing molecule, as it favored the clearance of CFTR aggre-
gates.11,12 Therefore, the recognition of the role of autophagy 
in B. cepacia infection will lead to the development of a novel 
class of therapeutic agents that will clear CF aggregates and B. 
cepacia infection simultaneously.77,78 Thus, our findings have the 
potential for clinical application in CF patients who currently 
have limited options for treatment of B. cepacia infection and its 
associated deleterious inflammation.
Materials and Methods
Bone-marrow-derived macrophages. All animal experiments 
were performed according to protocols approved by the Animal 
Care Use Committee of the Ohio State University College 
of Medicine. Wild-type (WT) C57BL/6, ΔF508 mice were 
obtained from Case Western University and housed in the OSU 
vivarium. Bone marrow-derived macrophages (BMDMs) were 
isolated from the femurs of 6- to 12-wk-old mice and were cul-
tured in IMDM (GIBCO, 12440) containing 10% heat-inacti-
vated FBS (GIBCO, 16000), 20% L cell-conditioned medium, 
100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO, 
15140) at 37°C in a humidified atmosphere containing 5% 
CO
2
. Macrophages were infected with B. cepacia K56-2 or the 
More IL-1β is produced from ΔF508 macrophages than WT 
macrophages during B. cepacia infection. This could be due to 
increased B. cepacia burden in ΔF508 macrophages. It is also pos-
sible that IL-1β release is higher in ΔF508 cells due to defective 
autophagy irrespective of the bacterial burden as suggested by a 
study demonstrating that autophagy regulates IL-1β secretion in 
response to lipopolysaccharide (LPS) by targeting pro-IL-1β for 
degradation.75,76 It is also plausible that both factors contribute 
to excess IL-1β production in ΔF508 macrophages infected with 
B. cepacia.
We found that rapamycin treatment reduces the production 
of inflammatory cytokines in vitro. H&E stained sections of 
infected lungs showed few focal regions of inflammation within 
WT infected lungs with the preservation of some healthy lung 
tissue. In contrast, stained sections of ΔF508 lungs showed the 
accumulation of inflammatory cells in the peribronchiolar and 
perivascular areas. Alveolar spaces were filled with inflammatory 
cells and with exudates. Treatment of WT mice with rapamycin 
pre- and post-infection improved the preservation of healthy lung 
tissue. The effect of rapamycin treatment on CF lungs was most 
impressive because the lungs of CF mice treated with rapamy-
cin were spared from the diffuse and intense inflammatory infil-
trate observed in mice that did not receive rapamycin. Recent 
work has showed that human and mouse CF airway epithelia 
Figure 6. treatment with rapamycin markedly decreases the recovery of B. cepacia from infected lungs of mice harboring ΔF508 mutation in vivo. 
Wild-type (Wt) (A) and mice harboring the ΔF508 mutation (ΔF508) (B) were pretreated with 2 doses of rapamycin (4 mg/kg) or with DMso at a 24 h 
interval by intra-peritoneal injections. then, mice were infected intra-tracheally with B. cepacia followed by a dose of rapamycin or DMso. colony-
forming units (cFUs) recovered from homogenized lungs were enumerated and expressed as cFU per gram of lung tissue (A and B). (c) h&e staining 
of lung sections from Wt (upper parts X40) or ΔF508 mice (middle parts X40) treated as in (A and B). Lower part shows higher magnification (X100) of 
infected ΔF508 lung sections. Data in (A and B) are represented as the means of data obtained from 3 mice ± sD. Asterisks indicate significant differ-
ences from the DMso treated mice (*p < 0.05).
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enumerate intracellular bacteria, infected macrophages were 
lysed using ice cold PBS (GIBCO, 14190) and physical disrup-
tion. Macrophages from monolayers were scrapped and pipetted 
repeatedly against the walls and bottom of the well. Recovered 
bacteria were quantified by plating serial dilutions on LB agar 
plates and counting colonies using the Acolyte Colony Counter, 
5710/SYN.
Mouse in vivo infection. WT C57BL/6 and ΔF508 mice 
were infected intra-tracheally with 10 x 106 WT bacteria with 
rapamycin (Sigma-Aldrich, R0395) or DMSO (Sigma-Aldrich, 
D2650) treatment (n = 3). Rapamycin was used in vivo at 4 mg/
kg by intra-peritoneal injections. Mice were pretreated with two 
corresponding gentamicin sensitive strain MHK1 at a multiplic-
ity of infection (MOI) of 10.
Bacterial strains and culture. Burkholderia cepacia strain 
K56-2 was isolated from a CF patient. All bacterial strains were 
grown in Luria-Bertani (LB) broth at 37°C overnight with high 
amplitude shaking. The B. cepacia MHK1 strain has a mutation 
in an antibiotic efflux pump that confers gentamicin sensitiv-
ity but does not alter the trafficking of the mutant in macro-
phages.79 To kill extracellular bacteria, Iscove’s media (GIBCO, 
12440) containing 10% heat-inactivated FBS (GIBCO, 
16000) containing 50 μg/ml gentamicin (GIBCO, 3564) was 
added for 30 min as previously described in reference 79. To 
Figure 7. treatment with rapamycin increases B. cepacia colocalization with Lc3/Atg8 and with lysosomes. Bone marrow derived macrophages 
(BMDM) from wild-type (Wt) and BMDM harboring ΔF508 mutation (ΔF508) were treated with rapamycin or DMso for 1 h before infection, and then 
macrophages were infected with B. cepacia for 2 h. (A) confocal microscopy demonstrates nuclei stained with DAPi, Lc3 stained green and B. cepacia 
expressing monomeric red florescent protein (mrFP). White arrows indicate the sites of colocalization with of B. cepacia with Lc3 with or without 
rapamycin. White arrows indicate colocalization, white arrow heads indicate B. cepacia. (B) scoring of the percentage of colocalization of B. cepacia 
with Lc3 with or without rapamycin treatment. (c) scoring of the percentage of colocalization of B. cepacia with Lystracker Green with or without 
rapamycin. (D) confocal microscopy showing nuclei stained with DAPi, lysosomes with Lysotracker Green and mrFP-expressing B. cepacia. the site 
of colocalization of B. cepacia with Lysotracker Green in ΔF508 macrophages upon rapamycin (ΔF508 + rapamycin) or DMso (ΔF508 + DMso) are 
indicated with white arrows. Data are representative of 3 independent experiments and presented as the means ± sD. Asterisks in (B and c) indicate 
significant differences from the DMso-treated cells (*p < 0.05; **p < 0.01; ***p < 0.001).
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formalin was replaced by PBS (GIBCO, 14190), and processed 
for paraffin embedding. Formalin-preserved sections of the lungs 
we processed and embedded in paraffin by standard techniques. 
Sections of 5 μm thick were stained with hematoxylin and eosin 
(H&E) and examined. Longitudinal sections of 5 μm taken at 
regular intervals were obtained using a microtome from the prox-
imal, medial and distal lung regions.
Confocal microscopy. Immunofluorescence microscopy 
experiments were performed as previously described in refer-
ence 84. B. cepacia expressing monomeric Red Fluorescent 
Protein (mRFP) was used. Localization of markers on B. cepa-
cia phagosomes was performed as previously described in refer-
ences 14 and 63. Antibodies used were rabbit anti-Atg8/LC3 
(Abgent, AP1805a) followed by fluorescent secondary antibod-
ies (Molecular Probes, A11008). Nuclei were stained with the 
nucleic acid dye 4',6'-diamino-2-phenylindole and lysosomes 
were stained green with Lysotracker Green (Invitrogen, L-7526) 
as previously described in references 14, 63, 80 and 85. In each 
experiment at least 100 bacteria were scored. Experiments 
were performed at least three times. Samples were analyzed 
with (Olympus FV 1000 Spectral Confocal) at the Ohio State 
University Microscopy Core Facility.
Transmission electron microscopy. WT and ΔF508 pri-
mary murine macrophages cultured on Permanox (Lab-Tek) 
chamber slides were fixed with 2.5% glutaraldehyde in 0.1 M 
phosphate buffer with 0.1 M sucrose. The cells were postfixed 
with 1% osmium tetroxide in phosphate buffer and then en bloc 
stained with 2% uranyl acetate in 10% ethanol, dehydrated in 
a graded series of ethanol and embedded in Eponate 12 epoxy 
resin (Ted Pella Inc., 18012). Ultrathin sections were cut on a 
Leica EM UC6 ultramicrotome (Leica microsystems, EM FC7), 
collected on copper grids, and then stained with Lead citrate 
and rranyl acetate. Images were acquired with an FEI Technai 
G
2
 Spirit transmission electron microscope (FEI), and Macrofire 
(Optronics) digital camera and AMT image capture software.
Statistical analysis. All experiments were performed at least 
three independent times and yielded similar results. Comparisons 
of groups for statistical difference were done using Student’s two-
tailed t test. p value ≤ 0.05 was considered significant.
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doses of rapamycin for 2 d (24 h interval), and then infected 
with B. cepacia 2 h after the second dose of rapamycin. On the 
third day, mice treated with a final dose of rapamycin. The mice 
were sacrificed 2 h later, and the number of bacteria in the lungs 
was determined at second day post-infection.14 All animal experi-
ments were performed according to animal protocols approved 
by the Animal Care Use Committee of the Ohio State University 
College of Medicine.
In vitro rapamycin treatment. Rapamycin (Sigma-Aldrich, 
R0395) was dissolved in DMSO (Sigma-Aldrich, D2650) at 
1 mg/ml. Rapamycin was used at concentration 5 μg/ml, DMSO 
alone was used as a diluent control.
Immunoblotting. Macrophages were stimulated with B. cepa-
cia K56-2 (MHK1) and the culture supernatant was removed. The 
cells were washed twice with PBS (GIBCO, 14190) and lysed in 
lysis buffer solution supplemented with a protease inhibitor mix-
ture (Roche Applied Science, 10-519-978-001). The protein con-
centration was adjusted to 40 μg/ml. Proteins were separated by 
sodium dodecyl sulfate-15% PAGE and transferred to polyvinyli-
dene difluoride (PVDF) membranes (Bio-Rad Laboratories, 162-
0117). Membranes were immunoblotted for pro-Interleukin-1β 
(IL-1β) antibody (kindly provided by Dr. Mark Wewers, Ohio 
State University) and Atg8 (LC3) (Sigma-Aldrich, L8918) pro-
tein bands were detected with secondary antibodies conjugated 
to horseradish peroxidase followed by enhanced chemilumines-
cence reagents (Amersham ECL protein gel blotting detection 
reagents GE Health Care-Life Sciences, RPN2106).
Enzyme-linked immuno sorbent assay (ELISA). Macrophages 
were infected with B. cepacia K56-2 (MH1K) for different time 
points 6, 8, 24 h. Then, culture supernatants were collected, cen-
trifuged and stored at -20°C until assayed for cytokine content. 
The amounts of IL-1β, IL-6 and TNFα in the supernatant were 
determined by specific sandwich ELISA following the manu-
facturer’s protocol (R&D System Inc., DY201, DY406, DY410 
respectively) and as previously described in reference 80.
siRNA knockdown of LC3. siRNA treatment was performed 
using siRNA against LC3 (Dharmacon, J-040989-09): CUA 
AUA AAG GCA CAA CGA A, GGA UAU AGC UCU AAG 
CCG G, CAU CCU AAG UUG CCA AUA A, ACU AUG 
GUG CGA UCA GUA A. siRNA was nucleofected into primary 
murine macrophages using Lonza Nucleofection kit (VPA-1009) 
and Amaxa equipment (AAD-10015) as we described previously 
in references 81 and 82.
Real time PCR. Total RNA was isolated from cells were lysed 
in Trizol (Invitrogen Life Technologies, 15596-026) and submit-
ted to SA Biosciences for autophagy array study. Gene expression 
was calculated as relative copy numbers (RCN), as described pre-
viously in references 81 and 83. Briefly, Ct values of every target 
gene were subtracted from the average Ct of five housekeeping 
genes, present on the autophagy array (Gusb, Hprt1, Hsp90ab1, 
Gapdh, Actb) and the resulted ΔCt was used in the equation: 
RCN = (2-ΔCt) x 100. RCN for every gene represents its expression 
as number of copies relative to the 100 copies of average house-
keeping genes.81,83
Histopathological analysis. Lungs were removed en bloc 
and fixed in (10% Formalin) at room temperature for 24 h then 
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Note
Supplemental material can be found at: 
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Note
This study was performed in strict accordance with the recom-
mendations in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. Our protocol num-
ber 2007A0070 has been approved by the OSU Institutional 
Animal Care and Use Committee (IACUC). All efforts were 
made to minimize suffering.
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